Menu
sharewise sharewise
Log in
Sign up
Log in
Sign up
Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.
  1. Predictions
buy

Reata Pharmaceuticals Inc buy tamam

Reata Pharmaceuticals Inc
Start price
€23.80
18.01.18 / 50%
Target price
€220.00
04.11.21
Performance (%)
263.45%
End price
€86.50
05.11.21
Summary
This prediction ended on 05.11.21 with a price of €86.50. With a performance of 263.45% the BUY prediction by tamam was a big success. tamam has 50% into this prediction

Reata Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company that focuses on identifying, developing, and commercializing novel therapeutics for patients with severe and life-threatening diseases. The company's primary business areas include drug discovery and development in fields such as cardiovascular, fibrotic, mitochondrial, and neurodegenerative diseases. With a strong emphasis on research and innovation, Reata Pharmaceuticals seeks to deliver cutting-edge treatments that address unmet medical needs, improve patient outcomes, and significantly impact the lives of those suffering from rare and debilitating conditions. As a publicly traded company, Reata Pharmaceuticals is listed on the NASDAQ stock exchange under the ticker symbol "RETA."

Performance without dividends (%)
Name 1w 1m 1y 3y
Reata Pharmaceuticals Inc - - - -
iShares Core DAX® 1.804% -0.748% 13.168% 16.408%
iShares Nasdaq 100 -0.182% -3.412% 39.976% 43.502%
iShares Nikkei 225® 0.413% -7.381% 18.776% 2.874%
iShares S&P 500 0.664% -1.941% 28.141% 42.155%

Comments by tamam for this prediction

In the thread Reata Pharmaceuticals Inc diskutieren
Prediction Buy
Perf. (%) 263.45%
Target price 98.000
Change
Ends at 04.11.21

Reata Pharmaceuticals Hits A Double With 2 Positive Mid-Stage Results For Chronic Kidney Disease


Reata Pharmaceuticals obtains positive results for both phase 2 studies dealing with two rare forms of chronic kidney disease.

Both phase 2 studies were shown to greatly increase eGFR, which bodes well for incoming late-stage studies.
Phase 2 Data for Alport Syndrome study reveal that bardoxolone has the potential for accelerated approval which should greatly speed up FDA approval.
Both Alport Syndrome and Autosomal dominant polycystic kidney disease only have treatments that take care of the symptoms, however, bardoxolone has the ability treat the diseases themselves.
The financials are in good shape now because Reata has increased its term loan facility to $125 million, and just announced it would sell 3 million shares of its Class A common stock.


Update: Oct. 14, 2019   Reata Pharmaceuticals (NASDAQ:RETA) announces positive results from the registrational portion of its Phase 2 clinical trial, MOXIe, evaluating omaveloxolone in patients with a rare inherited neurodegenerative disorder called Friedreich's ataxia (FA).
The study met the primary endpoint of the change in the modified FA Rating Scale (mFARS) at week 48 versus placebo. The treatment effect was time-dependent with the most significant improvement observed after 48 weeks.



    



        



        



        



        




tamam 
0
Report Share
18.01.18
Prediction Buy
Perf. (%) 263.45%
Target price 200.000
Change
Ends at 04.11.21

Kursziel geändert auf 200,0

tamam 
0
Report Share
06.11.19
Prediction Buy
Perf. (%) 263.45%
Target price 220.000
Change
Ends at 04.11.21

Kursziel geändert auf 220,0

tamam 
0
Report Share
17.12.19
In the thread Trading Reata Pharmaceuticals Inc
Prediction Buy
Perf. (%) 263.45%
Target price 220.000
Change
Ends at 04.11.21

Die von tamam gewählte maximale Laufzeit wurde überschritten

tamam 
0
Report Share
05.11.21